C([NH:5][C:6]([C:8]1[CH:9]=[C:10]2[C:15](=[CH:16][CH:17]=1)[N:14]=[C:13]([C:18]1[CH:23]=[CH:22][C:21]([F:24])=[CH:20][CH:19]=1)[C:12]([N:25]1[CH2:29][CH2:28][CH2:27][C@@H:26]1[CH3:30])=[N:11]2)=O)(C)(C)C.C(OC(C(F)(F)F)=O)(C(F)(F)F)=O>ClCCl>[F:24][C:21]1[CH:22]=[CH:23][C:18]([C:13]2[C:12]([N:25]3[CH2:29][CH2:28][CH2:27][C@@H:26]3[CH3:30])=[N:11][C:10]3[C:15](=[CH:16][CH:17]=[C:8]([C:6]#[N:5])[CH:9]=3)[N:14]=2)=[CH:19][CH:20]=1To a solution of (S)—N-tert-butyl-2-(4-fluorophenyl)-3-(2-methylpyrrolidin-1-yl)quinoxaline-6-carboxamide (160 mg, crude) in dichloromethane (30 mL) was added TFAA (4 mL). The resulting solution was stirred overnight at room temperature and then quenched by the addition water (100 mL), adjusted to pH 7 with sodium bicarbonate, and extracted with dichloromethane (3×30 mL). The organic layers combined and dried over anhydrous sodium sulfate and concentrated in vacuo to (S)-2-(4-fluorophenyl)-3-(2-methylpyrrolidin-1-yl)quinoxaline-6-carbonitrile as a yellow solid (100 mg, 53%).